Anti-Tet2 antibody - N-terminal (ab230358)
Key features and details
- Rabbit polyclonal to Tet2 - N-terminal
- Suitable for: IHC-P, WB, IP, ICC/IF, ChIP
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-Tet2 antibody - N-terminal
See all Tet2 primary antibodies -
Description
Rabbit polyclonal to Tet2 - N-terminal -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, WB, IP, ICC/IF, ChIPmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human Tet2 (N terminal). The exact sequence is proprietary.
Database link: Q6N021 -
Positive control
- ChIP: U-2 OS chromatin extract; WB: HEK-293T, A431, HeLa and HepG2 whole cell lysate; DDDDK-human Tet2-transfected HEK-293T whole cell lysate; IHC-P:Human breast cancer and cervical carcinoma tissues; IF: HeLa cells; IP: HEK-293T whole cell lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.00
Preservative: 0.025% Proclin 300
Constituents: 79% PBS, 20% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab230358 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/100 - 1/1000.
|
|
WB |
1/500 - 1/3000. Predicted molecular weight: 224 kDa.
|
|
IP |
1/100 - 1/500.
|
|
ICC/IF |
1/100 - 1/1000.
|
|
ChIP |
Use at an assay dependent concentration.
|
Notes |
---|
IHC-P
1/100 - 1/1000. |
WB
1/500 - 1/3000. Predicted molecular weight: 224 kDa. |
IP
1/100 - 1/500. |
ICC/IF
1/100 - 1/1000. |
ChIP
Use at an assay dependent concentration. |
Target
-
Function
Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. -
Tissue specificity
Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes. -
Involvement in disease
Note=TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites.
Defects in TET2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
Note=TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen.
Note=TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. -
Sequence similarities
Belongs to the TET family. - Information by UniProt
-
Database links
- Entrez Gene: 54790 Human
- Omim: 612839 Human
- SwissProt: Q6N021 Human
- Unigene: 367639 Human
-
Alternative names
- FLJ20032 antibody
- KIAA1546 antibody
- MDS antibody
see all
Images
-
Cross-linked ChIP was performed with U-2 OS (human bone osteosarcoma epithelial cell line) chromatin extract and 5 μg of either control rabbit IgG or ab230358. The precipitated DNA was detected by PCR with primer set targeting to CCND2.
-
All lanes : Anti-Tet2 antibody - N-terminal (ab230358) at 1/500 dilution
Lane 1 : HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 2 : A431 (Human epidermoid carcinoma cell line) whole cell lysate
Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 4 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate
Lysates/proteins at 30 µg per lane.
Secondary
All lanes : HRP-conjugated anti-rabbit IgG
Predicted band size: 224 kDa5% SDS-PAGE gel.
-
Paraffin-embedded human cervical carcinoma tissue stained for Tet2 using ab230358 at 1/500 dilution in immunohistochemical analysis.
Antigen Retrieval: EDTA based buffer, pH 8.0, 15min.
-
Immunofluorescence analysis of 4% paraformaldehyde-fixed HeLa (human epithelial cell line from cervix adenocarcinoma) cells labeling Tet2 (green) with ab230358 at 1/1000 dilution.
Counterstain: Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin antibody at 1/1000 dilution. Blue: Hoechst 33342 staining.
-
All lanes : Anti-Tet2 antibody - N-terminal (ab230358) at 1/5000 dilution
Lane 1 : HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell extract
Lane 2 : DDDDK-human Tet2-transfected HEK-293T whole cell lysate
Lysates/proteins at 30 µg per lane.
Secondary
All lanes : HRP-conjugated anti-rabbit IgG
Predicted band size: 224 kDa5% SDS-PAGE gel.
-
Paraffin-embedded human breast cancer tissue stained for Tet2 using ab230358 at 1/500 dilution in immunohistochemical analysis.
Antigen Retrieval: EDTA based buffer, pH 8.0, 15min.
-
Tet2 was immunoprecipitated from HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate with 5 µg ab230358. Western blot was performed from the immunoprecipitate using ab230358. Anti rabbit IgG antibody was used as secondary antibody.
Lane 1: Control IgG IP in HEK-293T whole cell lysate.
Lane 2: ab230358 IP in HEK-293T whole cell lysate.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab230358 has been referenced in 3 publications.
- Li J et al. lncRNA DARS-AS1 Modulates TSPAN1-Mediated ITGA2 Hypomethylation by Interaction with miR-194-5p Thus Promoting Ovarian Cancer Progression. Stem Cells Int 2022:4041550 (2022). PubMed: 36187230
- Chen L et al. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia. RNA Biol 17:784-793 (2020). PubMed: 32174258
- Zhou K et al. Potential role of TET2 in gastric cancer cisplatin resistance. Pathol Res Pract 215:152637 (2019). PubMed: 31570278